Selective COX-2 inhibitors: a health economic perspective.

摘要: The use of nonsteroidal anti-inflammatory drugs (NSAIDs) is common in patients with osteoarthritis and rheumatoid arthritis. However, due to gastrointestinal side effects, the health-related economic burden related these considerable. Therefore, substituting or supplementing conventional NSAIDs safer that have a better risk profile not only may avoid serious complications but also be an efficient allocation scarce resources. Because their profile, newly developed selective COX-2 inhibitors celecoxib rofecoxib are discussed as cost-effective alternatives NSAIDs. This paper provides overview health evaluations, conducted during last few years, investigate consequences switching from traditional inhibitors. review literature shows results assessments highly contradictory. main divergence between studies occurs estimated adopting at low average for developing effects. introduction well asynchronous development scientific acceptance benefit new actual diffusion spread taking broader, healthcare-system perspective.